Dear Ms. Christoforides:

Please refer to your supplemental new drug applications dated March 28, 2002, received April 3, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Avelox® (moxifloxacin) Tablets, 400 mg and Avelox® (moxifloxacin) Injection, 400 mg/250 ml 0.8% saline.

These as “Changes Being Effected (CBE)” supplemental new drug applications provide for the following changes to the package insert. Delete text is noted by strikethrough and added text is noted by double underline:

1. **WARNINGS**
   - The last paragraph in this section was revised to read:

   Although not observed in moxifloxacin clinical trials, Achilles and other tendon ruptures that required surgical repair or resulted in prolonged disability have been reported with quinolones. Post-marketing surveillance reports indicate that the risk may be increased in patients receiving concomitant corticosteroids, especially in the elderly. Moxifloxacin should be discontinued if the patient experiences pain, inflammation, or rupture of a tendon.

2. **ADVERSE REACTIONS**
   - Abdominal pain was deleted from “BODY AS A WHOLE”.

   - “Maculopapular, purpuric, pustular” were added to “rash” in SKIN/APPENDAGES”.
The following paragraph was reordered and revised to read:

Additional clinically relevant rare events, judged by investigators to be at least possibly drug-related, that occurred in less than 0.1% of moxifloxacin treated patients were: pelvic pain, face edema, vasodilation, hypotension, hallucinations, depersonalization, hypertonia, incoordination, agitation, amnesia, ventricular tachycardia, atrial fibrillation, supraventricular tachycardia, abnormal dreams, abnormal vision, agitation, amblyopia, amnesia, anemia, aphasia, arthritis, asthma, atrial fibrillation, convulsions, depersonalization, depression, diarrhea (*Clostridium difficile*), dysphagia, ECG abnormal, emotional lability, aphasia, thinking abnormal, abnormal dreams, abnormal vision, convulsions, depression, gastritis, tongue discoloration, dysphagia, jaundice, diarrhea (*Clostridium difficile*), prothrombin increase, anemia, face edema, gastritis, hallucinations, hyperglycemia, hyperlipidemia, hypertension, hyperuricemia, arthritis, tendon disorder, asthma, tinnitus, parosmia, taste loss, amblyopia, hypesthesia, hypotension, incoordination, jaundice, kidney function abnormal, urticaria, parosmia, pelvic pain, prothrombin increase, sleep disorders, speech disorders, supraventricular tachycardia, taste loss, tendon disorder, thinking abnormal, thromboplastin decrease, tinnitus, tongue discoloration, urticaria, vasodilatation, ventricular tachycardia.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the final printed labeling submitted on March 28, 2002. Accordingly, these supplemental applications are approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.
If you have any questions, call Robin Anderson, Labeling Reviewer, at (301) 827-2127.

Sincerely,

{See appended electronic signature page}

Renata Albrecht, M.D.
Acting Director
Division of Special Pathogen and Immunologic Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

____________________
Renata Albrecht
5/16/02 12:02:07 PM